European journal of gastroenterology & hepatology · 2026
External validation of a prediction score for identifying a mild course of Crohn's disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Couto Sousa Diogo, Fernandes Samuel Raimundo, Da Silva Neves André, Pereira Filipa, Bronze Sérgio, Coelho Rodrigues Inês, Saraiva Sofia, Gonçalves Ana Rita, Valente Ana, Correia Luís
Аннотация
INTRODUCTION: Crohn's disease has a heterogeneous course. Early identification of patients likely to follow a mild trajectory remains challenging. The prediction score for a mild course of Crohn's disease (PreMiCC) was recently proposed, but external validation is lacking.
METHODS: This single-center retrospective study included patients diagnosed with Crohn's disease between 2004 and 2024. The PreMiCC score was calculated at diagnosis using the original variables: age, C-reactive protein, perianal disease, endoscopic severity, and complications. Patients were classified as having a score ≤2 or >2. Outcomes included mild disease course, need for biologic therapy, Crohn's disease-related surgery or hospitalization, and time to treatment escalation.
RESULTS: A total of 342 patients (51% male; mean age 35 ± 16 years) were included, with a mean follow-up of 9 ± 5 years. At diagnosis, 55% had a PreMiCC score ≤2. A mild disease course occurred in 31% of patients and was more common in those with a score ≤2 than >2 (42% vs. 17%; P < 0.001). Patients with a score >2 more frequently required biologic therapy (80% vs. 54%; P < 0.001) and hospitalization (15% vs. 7%; P = 0.023), whereas the need for surgery did not differ between groups (20% vs. 17%; P = 0.415). The PreMiCC score independently predicted biologic therapy [odds ratio = 1.65, 95% confidence interval (CI) = 1.33-2.04; P < 0.001]. Time to treatment escalation was shorter in patients with a score >2 (log-rank P < 0.001). The model showed acceptable discrimination (area under the receiver operating characteristic curve = 0.708, 95% CI = 0.649-0.768), with 74% sensitivity, 55% specificity, 42% positive predictive value, and 83% negative predictive value.
CONCLUSION: This first external validation confirms the predictive value of the PreMiCC score in a real-world cohort, supporting its use as a simple tool for early risk stratification in Crohn's disease.
METHODS: This single-center retrospective study included patients diagnosed with Crohn's disease between 2004 and 2024. The PreMiCC score was calculated at diagnosis using the original variables: age, C-reactive protein, perianal disease, endoscopic severity, and complications. Patients were classified as having a score ≤2 or >2. Outcomes included mild disease course, need for biologic therapy, Crohn's disease-related surgery or hospitalization, and time to treatment escalation.
RESULTS: A total of 342 patients (51% male; mean age 35 ± 16 years) were included, with a mean follow-up of 9 ± 5 years. At diagnosis, 55% had a PreMiCC score ≤2. A mild disease course occurred in 31% of patients and was more common in those with a score ≤2 than >2 (42% vs. 17%; P < 0.001). Patients with a score >2 more frequently required biologic therapy (80% vs. 54%; P < 0.001) and hospitalization (15% vs. 7%; P = 0.023), whereas the need for surgery did not differ between groups (20% vs. 17%; P = 0.415). The PreMiCC score independently predicted biologic therapy [odds ratio = 1.65, 95% confidence interval (CI) = 1.33-2.04; P < 0.001]. Time to treatment escalation was shorter in patients with a score >2 (log-rank P < 0.001). The model showed acceptable discrimination (area under the receiver operating characteristic curve = 0.708, 95% CI = 0.649-0.768), with 74% sensitivity, 55% specificity, 42% positive predictive value, and 83% negative predictive value.
CONCLUSION: This first external validation confirms the predictive value of the PreMiCC score in a real-world cohort, supporting its use as a simple tool for early risk stratification in Crohn's disease.